Gemma Mudd

626 citations

24 papers · 401 indexed · h-index 10

Impact in

Radiology, Nuclear Medicine and Imaging top 10%
- Monoclonal and Polyclonal Antibodies Research
Oncology
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research

Papers in ⓘ

Radiology, Nuclear Medicine and Imaging 13
- Monoclonal and Polyclonal Antibodies Research 12
Immunology 7
- Toxin Mechanisms and Immunotoxins 4

Co-authors: Liuhong Chen (12 shared papers)Katerine Van Rietschoten (9 shared papers)Amy Brown (11 shared papers)Gavin Bennett (13 shared papers)Silvia Pavan (4 shared papers)Philip Huxley (8 shared papers)Nicholas Keen (14 shared papers)Johanna Lahdenranta (11 shared papers)
Journals: Cancer Research (8 papers)Molecular Cancer Therapeutics (4 papers)Journal of Medicinal Chemistry (3 papers)Analytical Chemistry (1 paper)Methods and Applications in Fluorescence (1 paper)
Partner nations: United Kingdom Germany Switzerland

In The Last Decade

Gemma Mudd

18 papers receiving 384 citations

Peers

Countries citing papers authored by Gemma Mudd

Since Specialization

Citations

This map shows the geographic impact of Gemma Mudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma Mudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma Mudd more than expected).

Fields of papers citing papers by Gemma Mudd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma Mudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma Mudd. The network helps show where Gemma Mudd may publish in the future.

Co-authors

The 25 scholars most cited alongside Gemma Mudd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gemma Mudd Line = papers co-authored together Gemma Mudd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	MMAE Delivery Using the Bicycle Toxin Conjugate BT5528 Molecular Cancer Therapeutics ·Gavin Bennett, Amy Brown, Gemma Mudd, Philip Huxley, Katerine Van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie Watcham, Johanna Lahdenranta, Nicholas Keen	2020	77
2	Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer Journal of Medicinal Chemistry ·Gemma Mudd, Heather S. Scott, Liuhong Chen, Katerine Van Rietschoten, Gabriela Ivanova-Berndt, Katarzyna Dzionek, Amy Brown, Sophie Watcham, Lewi White, Peter U. Park, Phil Jeffrey, Mike Rigby, Paul Beswick	2022	58
3	Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads Journal of Medicinal Chemistry ·Gemma Mudd, Amy Brown, Liuhong Chen, Katerine Van Rietschoten, Sophie Watcham, Daniel P. Teufel, Silvia Pavan, Rachid Lani, Philip Huxley, Gavin Bennett	2020	55
4	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors Cancer Research ·Matthias Eder, Silvia Pavan, Ulrike Bauder‐Wüst, Katerine Van Rietschoten, Ann-Christin Baranski, Helen Harrison, Spencer Campbell, Catherine Stace, Edward H. Walker, Liuhong Chen, Gavin Bennett, Gemma Mudd, Ursula Schierbaum, Karin Leotta, Uwe Haberkorn, Klaus Kopka, Daniel P. Teufel	2019	49
5	BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors Molecular Cancer Therapeutics ·Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma Mudd, Helen Harrison, Paul Beswick, Katerine Van Rietschoten, Sophie Watcham, Heather S. Scott, Amy Brown, Peter U. Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J. Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee	2022	41
6	Complementary Benzophenone Cross-Linking/Mass Spectrometry Photochemistry Analytical Chemistry ·Adam Belsom, Gemma Mudd, Sven H. Giese, Manfred Auer, Juri Rappsilber	2017	26
7	A general synthetic route to isomerically pure functionalized rhodamine dyes Methods and Applications in Fluorescence ·Gemma Mudd, Irene Pérez Pi, Nicholas Fethers, Peter G. Dodd, Olivier Barbeau, Manfred Auer	2015	22
8	Identification and X‐ray Co‐crystal Structure of a Small‐Molecule Activator of LFA‐1‐ICAM‐1 Binding Angewandte Chemie International Edition ·Martin Hintersteiner, Jörg Kallen, Mario Schmied, Christine Gräf, Thomas Jung, Gemma Mudd, Steven Shave, Hubert Gstach, Manfred Auer	2014	14
9	Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology Journal of Medicinal Chemistry ·Punit Upadhyaya, Julia Kristensson, Johanna Lahdenranta, Elizabeth Repash, Jun Ma, Jessica Kublin, Gemma Mudd, Lia Luus, Phil Jeffrey, Kristen E. Hurov, Kevin McDonnell, Nicholas Keen	2022	11
10	Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides Bioconjugate Chemistry ·Gemma Mudd, Steven J. Stanway, David R. Witty, Alex Thomas, Silvia Baldo, Andrew D. Bond, Paul Beswick, Adrian J. Highton	2022	10
11	Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide Theranostics ·Mohamed El Fakiri, Anusha Regupathy, Lisa Uhlmann, Nawal Ayada, Nicolas M. Geis, Lisa-Charlotte Domogalla, Johanna Lahdenranta, Ben Blakeman, Francesca Wood, Philipp T. Meyer, Philip Huxley, Matthias Eder, Gemma Mudd, Ann-Christin Eder	2024	9
12	Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models Molecular Cancer Therapeutics ·Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma Mudd, Paul Beswick, Helen Harrison, Sophie Watcham, Heather Allen, Amy Brown, Katerine Van Rietschoten, Philip Jeffrey, Peter U Park, Eric Haines, Nicholas Keen, Johanna Lahdenranta	2019	8
13	Towards mimicking short linear peptide motifs: identification of new mixed α,β-peptidomimetic ligands for SLAM-Associated Protein (SAP) by confocal on-bead screening PubMed ·Martin Hintersteiner, Andrew J. S. Knox, Gemma Mudd, Manfred Auer	2012	7
14	Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models Cancer Research ·Mike Rigby, Paul Beswick, Gemma Mudd, Katerine Van Rietschoten, Liuhong Chen, Sophie Watcham, Heather Allen, Amy Brown, Helen Harrison, Gavin Bennett, Phil Jeffrey, Peter U. Park, María Koehler, Nicholas Keen	2019	6
15	Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528 Cancer Research ·Gavin Bennett, Philip Huxley, Amy Brown, Gemma Mudd, Katerine Van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie Watcham, Peter U. Park, Nicholas Keen	2018	2
16	Abstract 4601: Development and clinical translation of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic applications Cancer Research ·Ann-Christin Eder, Mohamed Aymen Omrane, Anusha Regupathy, Mohamed El Fakiri, Nils Steinacker, Lisa-Charlotte Domogalla, Christoph‐Ferdinand Wielenberg, Michael Mix, Johanna Lahdenranta, Ben Blakeman, Francesca Wood, Philip Huxley, Gemma Mudd, Matthias Eder, Philipp T. Meyer, Martin T. Freitag	2025	1
17	Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models Cancer Research ·Gavin Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen	2019	1
18	Abstract 5854: BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models Cancer Research ·Gavin Bennett, Philip Huxley, Amy Brown, Gemma Mudd, Peter U. Park, Nicholas Keen	2018	1
19	Abstract C066: BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation Molecular Cancer Therapeutics ·Gavin Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen	2019	1
20	700 EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAs^TM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment SHILAP Revista de lepidopterología ·Kristen E. Hurov, Johanna Lahdenranta, Gemma Mudd, Punit Upadhyaya, Elizabeth Repash, Jun Ma, Julia Kristensson, Marianna Kleyman, Jessica Kublin, Liuhong Chen, Eric Haines, Sailaja Battula, Kevin McDonnell, Philip E. Brandish, Nicholas Keen	2020	1

About Gemma Mudd

Gemma Mudd is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology, Cellular and Molecular Neuroscience, Oncology and Molecular Biology, having authored 24 papers that have together received 401 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (12 papers), Chemical Synthesis and Analysis (6 papers), Click Chemistry and Applications (6 papers), Axon Guidance and Neuronal Signaling (6 papers), Peptidase Inhibition and Analysis (5 papers), Toxin Mechanisms and Immunotoxins (4 papers), Glycosylation and Glycoproteins Research (4 papers) and Signaling Pathways in Disease (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (136 citations), Oncology (155 citations), Molecular Biology (236 citations), Immunology and Allergy (17 citations) and Organic Chemistry (72 citations). Gemma Mudd has collaborated with scholars based in United Kingdom, Germany and Switzerland. Frequent co-authors include Liuhong Chen, Katerine Van Rietschoten, Amy Brown, Gavin Bennett, Silvia Pavan, Philip Huxley, Nicholas Keen, Johanna Lahdenranta, Manfred Auer and Paul Beswick. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, Analytical Chemistry and Methods and Applications in Fluorescence.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact